Literature DB >> 17384460

Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension.

Satoshi Akagi1, Hiromi Matsubara, Aiko Ogawa, Yusuke Kawai, Kenichi Hisamatsu, Katsumasa Miyaji, Mitsuru Munemasa, Yoshihisa Fujimoto, Kengo Fukushima Kusano, Tohru Ohe.   

Abstract

BACKGROUND: Most of the patients with pulmonary arterial hypertension (PAH) receiving intravenous epoprostenol have experienced catheter-related infections during long-term treatment. Catheter hub was reported to be the most important source of catheter-related infections. To prevent the catheter-related infections, we have introduced a closed hub system and compared the incidence of catheter-related infections with that in patients using a non-closed hub system. METHODS AND
RESULTS: We evaluated the results obtained on 24 occasions in 20 patients with PAH between June 1999 and December 2005. On 11 occasions, a non-closed hub system was used and on 13 cases a closed hub system. We classified the catheter-related infection into a catheter-related bloodstream infection (CRBSI) group or a tunnel infection group based on the pathway of bacteria. The CRBSI rate was 0.89 per 1,000 catheter days in the non-closed hub system group vs 0.10 per 1,000 catheter days in the closed hub system group. Kaplan-Meier analysis showed that the risk of CRBSI significantly decreased in the closed hub system group. None of the patients died as a direct consequence of catheter-related infection during the study period.
CONCLUSIONS: We successfully prevented CRBSI by using a closed hub system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384460     DOI: 10.1253/circj.71.559

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  10 in total

1.  The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension.

Authors:  Takashi Morishita; Katsumasa Miyaji; Izumi Akao; Keiji Fujita; Hiromi Nakayama; Kenichi Hisamatsu; Mitsuru Munemasa; Yoshihisa Fujimoto; Hiromi Matsubara
Journal:  J Med Ultrason (2001)       Date:  2009-08-15       Impact factor: 1.314

2.  Central venous catheter-related blood stream infections in patients receiving intravenous iloprost for pulmonary hypertension.

Authors:  D Sammut; C A Elliot; D G Kiely; I J Armstrong; L Martin; J Wilkinson; P Sephton; J Jones; N Hamilton; J Hurdman; E McLellan; I Sabroe; R Condliffe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-07       Impact factor: 3.267

3.  Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®.

Authors:  Natalie Kitterman; Abby Poms; Dave P Miller; Sandra Lombardi; Harrison W Farber; Robyn J Barst
Journal:  Mayo Clin Proc       Date:  2012-08-09       Impact factor: 7.616

4.  Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension.

Authors:  D Dunbar Ivy; Michelle Calderbank; Brandie D Wagner; Susan Dolan; Ann-Christine Nyquist; Michael Wade; William M Nickels; Aimee K Doran
Journal:  Infect Control Hosp Epidemiol       Date:  2009-09       Impact factor: 3.254

5.  Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension.

Authors:  A K Doran; D D Ivy; R J Barst; N Hill; S Murali; R L Benza
Journal:  Int J Clin Pract Suppl       Date:  2008-07

Review 6.  Epoprostenol sodium for treatment of pulmonary arterial hypertension.

Authors:  Yukihiro Saito; Kazufumi Nakamura; Satoshi Akagi; Toshihiro Sarashina; Kentaro Ejiri; Aya Miura; Aiko Ogawa; Hiromi Matsubara; Hiroshi Ito
Journal:  Vasc Health Risk Manag       Date:  2015-05-14

7.  Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy.

Authors:  Elisa K McCarthy; Michelle T Ogawa; Rachel K Hopper; Jeffrey A Feinstein; Hayley A Gans
Journal:  Pulm Circ       Date:  2018-01-08       Impact factor: 3.017

8.  Tsukamurella catheter-related bloodstream infection in a pediatric patient with pulmonary hypertension.

Authors:  Kristen A Wendorf; Claudia M Espinosa; William D Lebar; Jason B Weinberg
Journal:  Infect Dis Rep       Date:  2010-03-17

9.  Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.

Authors:  Satoshi Akagi; Kazufumi Nakamura; Hiromi Matsubara; Megumi Kondo; Daiji Miura; Tetsuya Matoba; Kensuke Egashira; Hiroshi Ito
Journal:  J Cardiovasc Pharmacol       Date:  2016-04       Impact factor: 3.105

10.  Bactericidal effects of deep ultraviolet light-emitting diode for solutions during intravenous infusion.

Authors:  Sachiko Omotani; Katsuji Tani; Mai Aoe; Seiji Esaki; Katsuhito Nagai; Yasutoshi Hatsuda; Junji Mukai; Hitomi Teramachi; Michiaki Myotoku
Journal:  Int J Med Sci       Date:  2018-01-01       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.